Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo CagriSema takes on tirzepatide in obesity showdown

NCT ID NCT06131437

Disease control Sponsor: Novo Nordisk A/S Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a new experimental drug called CagriSema (a combination of cagrilintide and semaglutide) against the existing drug tirzepatide for weight loss in 809 adults with obesity. Participants received weekly injections for about a year and a half. The goal was to see if CagriSema was at least as good as, or better than, tirzepatide at reducing body weight.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
CagriSema (cagrilintide and semaglutide combination)
What this could lead to
If it works, this could offer a more effective weight-loss option for people with obesity, potentially leading to greater and more sustained weight reduction than current treatments.
What could go wrong
This is a completed Phase 3 trial, but results are not yet published. The combination may cause more side effects than single drugs, and individual results vary. It is not a cure for obesity, only a management tool.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

809 people

The number who actually took part.

Started

Nov 2023

Finished

Jan 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female * Age 18 years or above at the time of signing the informed consent * Body mass index (BMI) of ≥ 30.0 kilogram per square meter (kg/m\^2) Exclusion Criteria: * Glycated haemoglobin (HbA1c) ≥ 6.5 % (48 millimoles per mole \[mmol/mol\]) as measured by the central laboratory at screening * History of type 1 or type 2 diabetes mellitus

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Obesity

Contacts and locations

Locations

  • Accellacare

    Wilmington, North Carolina, 28401, United States

  • Accellacare_NC

    Raleigh, North Carolina, 27609, United States

  • Amarillo Med Spec LLP

    Amarillo, Texas, 79124, United States

  • Baylr Sctt White Rs Inst, Endo

    Dallas, Texas, 75226, United States

  • Capital Clin Res Ctr,LLC

    Olympia, Washington, 98502, United States

  • Chambliss Clinical Trials LLC

    Montgomery, Alabama, 36106, United States

  • Clinical Res Collaborative

    Cumberland, Rhode Island, 02864, United States

  • Coastal Carolina Res Ctr

    North Charleston, South Carolina, 29405, United States

  • Comprehensive Weight Ctrl Prog

    New York, New York, 10021, United States

  • DCOL Ctr for Clin Res

    Longview, Texas, 75605, United States

  • Diablo Clinical Research, Inc.

    Walnut Creek, California, 94598, United States

  • East West Med Res Inst

    Honolulu, Hawaii, 96814, United States

  • Elligo Clin Res Centre

    Austin, Texas, 78704, United States

  • Endeavor Health

    Skokie, Illinois, 60077, United States

  • Evanston Premier Hlthcr Res

    Skokie, Illinois, 60077, United States

  • FDRC

    Costa Mesa, California, 92627, United States

  • Great Lakes Clinical Trials

    Chicago, Illinois, 60640, United States

  • Health Res of Hampton Roads

    Newport News, Virginia, 23606, United States

  • Hillcrest Clinical Research

    Simpsonville, South Carolina, 29681-1538, United States

  • Holston Medical Group

    Kingsport, Tennessee, 37660, United States

  • Holston Medical Group_Bristol

    Bristol, Tennessee, 37620, United States

  • Hope Clin Res & Wellness

    Conyers, Georgia, 30094, United States

  • Jacksonville Ctr For Clin Res

    Jacksonville, Florida, 32216, United States

  • Lynn Institute of Norman

    Norman, Oklahoma, 73072, United States

  • Medical University Of South Carolina

    Charleston, South Carolina, 29425, United States

  • Medication Mgmnt, LLC_Grnsboro

    Greensboro, North Carolina, 27405, United States

  • Midwest Inst For Clin Res

    Indianapolis, Indiana, 46260, United States

  • National Clin Res Inc.

    Richmond, Virginia, 23294, United States

  • New Venture Medical Research

    Wadsworth, Ohio, 44281, United States

  • Northeast Research Institute

    Fleming Island, Florida, 32003, United States

  • Northern Pines Hlth Ctr, PC

    Buckley, Michigan, 49620, United States

  • PharmQuest Life Sciences LLC

    Greensboro, North Carolina, 27408, United States

  • Rainier Clin Res Ctr Inc

    Renton, Washington, 98057, United States

  • Selma Medical Associates

    Winchester, Virginia, 22601-3834, United States

  • South Broward Research LLC

    Miramar, Florida, 33027, United States

  • Spartanburg Medical Research

    Spartanburg, South Carolina, 29303, United States

  • StudyMetrix Research LLC

    City of Saint Peters, Missouri, 63303, United States

  • The University of Penn Center

    Philadelphia, Pennsylvania, 19104-3317, United States

  • UT Health University of Texas

    Bellaire, Texas, 77401, United States

  • UT Southwestern Medical Center-CRU

    Dallas, Texas, 75390, United States

  • Univ of Alabama Birmingham

    Birmingham, Alabama, 35294, United States

  • Univ of Colorado at Denver

    Aurora, Colorado, 80045, United States

  • University of North Carolina

    Chapel Hill, North Carolina, 27514, United States

  • Velocity Clin Res, Dallas

    Dallas, Texas, 75230, United States

  • Washington Cntr Weight Mgmt

    Arlington, Virginia, 22206, United States

  • Yale University School Of Medicine

    New Haven, Connecticut, 06519, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.